Medications and Therapies

Review of clemastine's pro-myelination mechanisms: M1 receptor antagonism drives OPC differentiation; evidence from MS, TBI and stroke models

T3 availability is required for OPC-to-oligodendrocyte differentiation; MCT8 deficiency causes persistent hypomyelination and reduced Olig2+ cells at all developmental stages

TRbeta1 agonist TG68 drives OPC differentiation comparable to T3 under inflammatory conditions

IRX4204 (selective RXR agonist) restored gait deficits and promoted myelin repair in EAE without bexarotene's hyperlipidemia

Quetiapine 10 mg/kg/day improved spatial working memory and increased remyelination in the cuprizone mouse model

Agomelatine activates LRP1/PPARgamma in OPCs to drive differentiation and remyelination after stroke; no effect on proliferation

Paroxetine (SSRI) promotes OPC proliferation and differentiation and reduces myelin damage in a corticosterone depression model

Fingolimod triples OPC myelination in vitro; acts via lncRNAs Hotair/Malat1 to regulate BDNF expression in oligodendrocyte precursors

Mouse, preclinical. Fibronectin piling up in lesions traps OPCs short of repair; inhibiting it systemically restored remyelination and clinical remission.

Mouse ALS model. A brain-penetrant GPR17 agonist restored oligodendrocyte maturation, extended survival and improved motor function in females, with no benefit in males.

S1P receptor modulator approved for secondary progressive MS. S1P5 is expressed on oligodendrocytes, so a direct effect is plausible alongside the immune one.

An antimuscarinic antihistamine repurposed as a differentiation promoter. In this crossover trial it shortened visual evoked potential latency in chronic optic neuropathy, the first remyelination signal from a drug in humans.

Anti-CD20 B-cell depletion reduces relapse rate and new lesions in relapsing MS. Oligodendrocyte protection is indirect, by removing the immune attack.

The trial behind the first approval for primary progressive MS, a form with no previous disease-modifying option.

High-dose biotin as a cofactor for the carboxylases in myelin fatty acid synthesis. Later phase III work did not confirm the benefit; not approved.

High-throughput screen identifying benztropine and other antimuscarinics as OPC differentiation promoters. The origin of the clemastine hypothesis.

Stabilising Axin2 dampens Wnt signalling in OPCs and accelerates their maturation, linking a developmental pathway to a repair target.

RXR gamma is required for OPC differentiation; agonists accelerate remyelination in aged rodents. The retinoid pathway as a repair target.

Anti-VLA-4 blocks lymphocyte entry to the CNS. Carries PML risk, which is JC virus replicating in oligodendrocytes themselves.